European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Gavreto, pralsetinib, Date of authorisation: 18/11/2021, Revision: 8, Status: Withdrawn (authorisation)

Submitted by Anonymous (not verified) on 17 January 2025 - 16:15

Human medicines European public assessment report (EPAR): Gavreto, pralsetinib, Date of authorisation: 18/11/2021, Revision: 8, Status: Withdrawn (authorisation)

Regulation (EU) 2024/568: Questions and answers clinic for the Human Industry stakeholders, Online, European Medicines Agency, Amsterdam, the Netherlands, from 10 February 2025, 11:00 (CET) to 10 February 2025, 12:00 (CET)

Submitted by Anonymous (not verified) on 17 January 2025 - 15:44

Regulation (EU) 2024/568: Questions and answers clinic for the Human Industry stakeholders, Online, European Medicines Agency, Amsterdam, the Netherlands, from 10 February 2025, 11:00 (CET) to 10 February 2025, 12:00 (CET)

Human medicines European public assessment report (EPAR): Balversa, Erdafitinib, Date of authorisation: 22/08/2024, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 17 January 2025 - 15:41

Human medicines European public assessment report (EPAR): Balversa, Erdafitinib, Date of authorisation: 22/08/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 17 January 2025 - 15:30

Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 5, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More